Sunday, March 16, 2025 | 09:05 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Natco Pharma gains 4% on emergency use approval for Covid-19 medicine

The company has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India

Natco Pharma's formulations facility in Kothur
Premium

Natco Pharma's formulations facility in Kothur

SI Reporter Mumbai
Shares of Natco Pharma, on Monday, rose 4 per cent to Rs 935 on the BSE in intra-day trade after the company received emergency use approval for Baricitinib tablets for Covid-19 treatment.

“The company has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir is used for treatment of COVID-19 positive patients,” Natco Phamra said in exchange filing.

Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in